Why CEL-SCI Shares Are Shooting Higher Today

CEL-SCI Corporation CVM announced that the latest results from its pivotal Phase 3 study of Multikine, a presurgical cancer immunotherapy, were presented at the European Society for Radiotherapy and Oncology (ESTRO) 2023 Congress.

CEL-SCI's IT-MATTERS Phase 3 study reported a statistically significant 14.1% absolute 5-year overall survival benefit in the intent-to-treat (ITT) subjects who were categorized as a lower risk to recurrence (LR) and received Multikine followed by surgery and radiotherapy, as compared to control LR subjects who received only standard of care (SOC) (surgery plus radiotherapy).

Related: CEL-SCI's Lead Head & Neck Cancer Candidate Shows 43% Survival Extension.

The histopathology analysis showed an association with improved overall survival, progression-free survival, and local, regional control that significantly favored Multikine-treated [(61/279 or 21.9% >> 2.5% by chance alone) vs. SOC-treated (5/279 (or 1.9% < 2.5% by chance alone)].

Overall survival of 63.9% vs. 44.4%, with Progression Free Survival of 56.9%.

HP LR Multikine-treated subjects had a significantly lower (39.1% [45/115]) death rate versus a 53.7% (51/95) death rate for HP LR SOC alone.

Price Action: CVM shares are up 9.17% at $2.62 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!